Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AltimmuneMEX:ALT1 32 3-Year EBITDA Growth Rate is 18.10% as of Jun. 2026, which is 28% below its 10-year median of 25.00. GuruFocus rates MEX:ALT1 with a GF Score™ of 32/100 and a GF Value™ of MXN5.37 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,128 Biotechnology companies, Altimmune ranks better than 53.72% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 18.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 14.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 28.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Altimmune was 74.00% per year. The lowest was -68.10% per year. And the median was 25.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Altimmune 3-Year EBITDA Growth Rate Related Terms
MEX:ALT1 vs ARVN, AUTL, EIKN: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Altimmune's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Altimmune 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Altimmune's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Altimmune's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 18.10% mean?
Altimmune (MEX:ALT1) has a 3-Year EBITDA Growth Rate of 18.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Altimmune and its competitors. This is 28% below median its historical median of 25.00. According to the industry distribution chart, Altimmune ranks #522 out of 1128 companies in the Biotechnology industry, placing it in the top 46.3%.
Is Altimmune's 3-Year EBITDA Growth Rate too high?
Altimmune's current 3-Year EBITDA Growth Rate of 18.10% is 28% below median its 10-year median of 25.00. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.65. Altimmune's value of 18.10% is 23.5% above this industry median. Based on the distribution chart, Altimmune ranks #522 out of 1128 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Altimmune has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Altimmune's 3-Year EBITDA Growth Rate compare to ARVN and AUTL?
According to the Biotechnology industry distribution chart, Altimmune ranks #522 out of 1128 companies for 3-Year EBITDA Growth Rate. This puts Altimmune in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.65. Altimmune's value of 18.10% is 23.5% above this benchmark. While the company's 10-year median is 25.00 vs. the industry median of 14.65, Altimmune has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.65, based on 1,128 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Altimmune's current 3-Year EBITDA Growth Rate of 18.10% is 23.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Altimmune and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Altimmune's current 3-Year EBITDA Growth Rate is 18.10%, which is 28% below median its own 10-year median of 25.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altimmune stock overvalued right now?
Based on GuruFocus' analysis, Altimmune (MEX:ALT1) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN5.37, compared to a current price of MXN52.50 — trading 877.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 18.10%, which is 28% below median its 10-year median of 25.00 and 23.5% above the Biotechnology industry median of 14.65. Altimmune's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Altimmune (MEX:ALT1), the current 3-Year EBITDA Growth Rate is 18.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Altimmune (MEX:ALT1) Overvalued in 2026?
Based on GuruFocus' analysis, Altimmune stock appears to be overvalued.
The current stock price of MXN52.50 is trading 877.7% above its estimated GF Value™ of MXN5.37.
GuruFocus considers Altimmune to be Significantly Overvalued.
Key valuation signals for MEX:ALT1:
3-Year EBITDA Growth Rate: 18.10% (28% below median its 10-year median of 25.00)
GF Value™: MXN5.37 vs. price of MXN52.50 (877.7% above fair value)
Industry Position: 23.5% above the Biotechnology median (#522 of 1128)
No single metric tells the full story. See the MEX:ALT1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
32GF Score
Get the complete analysis for MEX:ALT1
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ALT1 has been successfully added to your 
